• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

机器人胰十二指肠切除术后医院再入院情况的机构分析

An institutional analysis of hospital readmission following a robotic pancreaticoduodenectomy.

作者信息

Gratsianskiy Denis, Patel Dharti, Sucandy Iswanto, Pattilachan Tara M, Christodoulou Maria, Rosemurgy Alexander, Ross Sharona B

机构信息

Foregut and HPB Division, Digestive Health Institute, AdventHealth Tampa, 3000 Medical Park Drive, Suite #500, Tampa, FL, 33613, USA.

出版信息

J Robot Surg. 2024 Dec 11;19(1):20. doi: 10.1007/s11701-024-02186-0.

DOI:10.1007/s11701-024-02186-0
PMID:39661231
Abstract

This study sought to identify the primary reasons for hospital readmissions and examine patient outcomes and associated costs following readmission after robotic pancreaticoduodenectomy. We conducted a retrospective analysis of 435 patients who underwent robotic pancreaticoduodenectomy between 2012 and 2024. Readmitted patients within 30 days post-surgery were compared to non-readmitted patients using Student's t-test and Fisher's exact test. Data are presented as median (mean ± SD). In the study cohort, 86 patients (20%) were readmitted within 30 days after surgery. No significant differences were found in patient demographics or outcomes. The most common causes for readmission included insufficient patient education (n = 18), infection (n = 16), and gastrointestinal bleeding (n = 13). The readmitted cohort had significantly higher costs at $40,452 (± 30,724) compared to $31,438 (± 31,546.2) for non-readmitted patients (p < 0.001). Median survival was similar between the two groups (36 vs. 34 months, p = 0.88). Although some readmissions are inevitable, this study provides compelling evidence that inadequate patient education is a primary contributor to increased healthcare costs. The lack of sufficient education appears to have no mitigating effect on patient outcomes. Implementing a proactive, thorough patient education approach, combined with improved emergency department awareness, presents a promising strategy for reducing costly readmissions.

摘要

本研究旨在确定医院再入院的主要原因,并检查机器人胰十二指肠切除术后再入院后的患者结局及相关费用。我们对2012年至2024年间接受机器人胰十二指肠切除术的435例患者进行了回顾性分析。采用学生t检验和Fisher精确检验,将术后30天内再入院的患者与未再入院的患者进行比较。数据以中位数(均值±标准差)表示。在研究队列中,86例患者(20%)在术后30天内再入院。患者人口统计学特征或结局方面未发现显著差异。再入院的最常见原因包括患者教育不足(n = 18)、感染(n = 16)和胃肠道出血(n = 13)。再入院队列的费用显著更高,为40,452美元(±30,724),而非再入院患者为31,438美元(±31,546.2)(p < 0.001)。两组的中位生存期相似(36个月对34个月,p = 0.88)。尽管有些再入院是不可避免的,但本研究提供了令人信服的证据,表明患者教育不足是医疗费用增加的主要原因。缺乏充分教育似乎对患者结局没有缓解作用。实施积极、全面的患者教育方法,同时提高急诊科的意识,是减少代价高昂的再入院的一个有前景的策略。

相似文献

1
An institutional analysis of hospital readmission following a robotic pancreaticoduodenectomy.机器人胰十二指肠切除术后医院再入院情况的机构分析
J Robot Surg. 2024 Dec 11;19(1):20. doi: 10.1007/s11701-024-02186-0.
2
Readmission and Resource Use After Robotic-Assisted versus Open Pancreaticoduodenectomy: 2010-2017.机器人辅助与开腹胰十二指肠切除术术后再入院和资源利用:2010-2017 年。
J Surg Res. 2020 Nov;255:517-524. doi: 10.1016/j.jss.2020.05.084. Epub 2020 Jul 3.
3
Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal.胰腺癌胰十二指肠切除术后的再入院情况:基于人群的评估。
Ann Surg Oncol. 2009 Mar;16(3):554-61. doi: 10.1245/s10434-008-0178-6. Epub 2008 Nov 11.
4
Open versus robot-assisted radical cystectomy: 30-day perioperative comparison and predictors for cost-to-patient, complication, and readmission.开放与机器人辅助根治性膀胱切除术:30 天围手术期比较以及对患者费用、并发症和再入院的预测因素。
J Robot Surg. 2019 Feb;13(1):129-140. doi: 10.1007/s11701-018-0832-3. Epub 2018 Jun 8.
5
Critical Analysis of Hospital Readmission and Cost Burden After Robot-Assisted Radical Cystectomy.机器人辅助根治性膀胱切除术后医院再入院及成本负担的批判性分析
J Endourol. 2016 Jan;30(1):83-91. doi: 10.1089/end.2015.0438. Epub 2015 Sep 25.
6
Readmission and complications after robotic surgery: experience of 10,000 operations at a comprehensive cancer center.机器人手术后的再入院和并发症:综合癌症中心 10000 例手术的经验。
J Robot Surg. 2021 Feb;15(1):37-44. doi: 10.1007/s11701-020-01077-4. Epub 2020 Apr 10.
7
Survival and Robotic Approach for Pancreaticoduodenectomy: A Propensity Score-Match Study.胰十二指肠切除术的生存情况及机器人手术入路:一项倾向评分匹配研究
J Am Coll Surg. 2022 Apr 1;234(4):677-684. doi: 10.1097/XCS.0000000000000137.
8
The Implications of Readmission on Cost and Patient Outcomes Following Distal Pancreatectomy and Splenectomy.远端胰腺切除术和脾切除术患者再入院对成本和患者结局的影响。
Am Surg. 2024 Apr;90(4):851-857. doi: 10.1177/00031348231216481. Epub 2023 Nov 14.
9
Nationwide outcomes and costs of laparoscopic and robotic vs. open hepatectomy.腹腔镜和机器人肝切除术与开腹肝切除术的全国性结果和成本。
J Robot Surg. 2019 Aug;13(4):557-565. doi: 10.1007/s11701-018-0896-0. Epub 2018 Nov 27.
10
Hospital readmissions after robotic hepatectomy for neoplastic disease: Analysis of risk factors, survival, and economical impact. A logistical regression and propensity score matched study.机器人辅助肝切除术治疗肿瘤性疾病后的医院再入院:危险因素、生存和经济影响的分析。逻辑回归和倾向评分匹配研究。
Am J Surg. 2024 Aug;234:92-98. doi: 10.1016/j.amjsurg.2024.03.014. Epub 2024 Mar 18.

引用本文的文献

1
Telesurgery across continents: a scoping review.跨洲远程手术:一项范围综述
J Robot Surg. 2025 Aug 30;19(1):536. doi: 10.1007/s11701-025-02694-7.

本文引用的文献

1
A comparative analysis of robotic versus open pancreaticoduodenectomy in octogenarians.高龄患者行机器人与开腹胰十二指肠切除术的对比分析。
J Robot Surg. 2024 Apr 26;18(1):183. doi: 10.1007/s11701-024-01952-4.
2
Deconstructing the Operative Times of Robotic Pancreaticoduodenectomy.解析机器人胰十二指肠切除术的手术时间。
Am Surg. 2024 Jun;90(6):1521-1530. doi: 10.1177/00031348241241705. Epub 2024 Apr 2.
3
Associations Between Patient Characteristics and Whipple Procedure Outcomes Before and After Implementation of an Enhanced Recovery After Surgery Protocol.
手术患者术后康复协议实施前后患者特征与胰十二指肠切除术结局的相关性。
J Gastrointest Surg. 2023 Sep;27(9):1855-1866. doi: 10.1007/s11605-023-05693-x. Epub 2023 May 10.
4
Costs and clinical benefits of enhanced recovery after surgery (ERAS) in pancreaticoduodenectomy: an updated systematic review and meta-analysis.胰十二指肠切除术后强化康复(ERAS)的成本和临床获益:更新的系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6639-6660. doi: 10.1007/s00432-022-04508-x. Epub 2023 Jan 11.
5
Readmission after pancreaticoduodenectomy: Birmingham score validation.胰十二指肠切除术后再入院:伯明翰评分验证
HPB (Oxford). 2023 Feb;25(2):172-178. doi: 10.1016/j.hpb.2022.08.002. Epub 2022 Aug 20.
6
Can a mobile app technology reduce emergency department visits and readmissions after lung resection? A prospective cohort study.移动应用程序技术能否减少肺切除术后急诊就诊和再入院?一项前瞻性队列研究。
Can J Surg. 2022 Nov 23;65(6):E798-E804. doi: 10.1503/cjs.000122. Print 2022 Nov-Dec.
7
A Decade of Observing the Hospital Readmission Reductions Program-Time to Retire an Ineffective Policy.观察医院再入院率降低计划的十年——是时候废除一项无效政策了。
JAMA Netw Open. 2022 Nov 1;5(11):e2242593. doi: 10.1001/jamanetworkopen.2022.42593.
8
Ambulatory colectomy: a pathway for advancing the enhanced recovery protocol.门诊结肠切除术:推进强化康复方案的途径。
J Robot Surg. 2023 Jun;17(3):827-834. doi: 10.1007/s11701-022-01463-0. Epub 2022 Nov 5.
9
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.FOLFIRINOX 对比吉西他滨作为胰腺癌辅助治疗的 5 年结果:一项随机临床试验。
JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829.
10
Predictors of postoperative complications and readmissions in laparoscopic pancreas resection: Results of a cohort 105 consecutive cases. A retrospective study.腹腔镜胰腺切除术术后并发症和再入院的预测因素:105 例连续病例的队列研究。一项回顾性研究。
Cir Esp (Engl Ed). 2023 May;101(5):333-340. doi: 10.1016/j.cireng.2022.04.015. Epub 2022 Apr 29.